

Schriftliche Frage Nr. 69 vom 22. Dezember 2015 von Herrn Balter an Herrn Minister Antoniadis bezüglich Studien zur Impfwirksamkeit*

Frage

Im Grenz-Echo Artikel vom 11.12.2015 weisen Sie darauf hin, dass es Fakt sei, dass Impfen Leben rettet, dass verschiedenen Infektionskrankheiten nur durch eine Schutzimpfung zu hundert Prozent vermieden werden könne und es wissenschaftlich korrekt durchgeführte Studien gibt, die dies belegen.

Bitte senden Sie uns die Kopien der Studien, die Ihre Aussagen belegen mit der genauen Quellenangabe zu.

Antwort

Zur Gestaltung ihrer Gesundheitspolitik stützt sich die Regierung der DG u.a. auf die Empfehlungen der WHO und des Hohen Rates für Gesundheit. Diese beruhen auf nationalen und internationalen Studien.

So können die folgenden allgemeinen Quellen und Studien aufgeführt werden:

Ansteckende Kinderkrankheiten, die vorgebeugt werden können durch Impfen: Tendenzen und Entwicklung in Belgien und den Gemeinschaften, 2013, WIV

Global vaccine action plan 2011-2020, WHO

Immunization work: highlights 2008-09, WHO

WHO Recommendations Regarding Vaccine Hesitancy, Vaccine Volume 33, Issue 34, Melanie Schuster & Philippe Duclos, 2015

Weitere Studien widmen sich dem Thema:

Benefits from immunization during the Vaccines for Children program era—United States, 1994-2013, Whitney CG, Zhou F, Singleton J, Schuchat A.

Vaccination Coverage Among Children in Kindergarten — United States, 2014-15, Seither R, Calhoun K, Knighton CL, Mellerson J, Meador S, Tippins A, et al.

Global Routine Vaccination Coverage, Subaiya S, Dumolard L, Lydon P, Gacic-Dobo M, Eggers R, Conklin L. 2014

Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies, Institut of Medecine, 2013

Progress Toward Polio Eradication — Worldwide, 2014-2015, Hagan JE, Wassilak SGF, Craig AS, Tangermann RH, Diop OM, Burns CC, et al

L'éradication des maladies infectieuses : l'exemple de la poliomyélite, Denise Antona, Medecine et Sciences, Volume 18, 2002

* Die nachfolgend veröffentlichten Texte entsprechen den hinterlegten Originalfassungen.

Das Impfschema der DG sieht die Impfung gegen Diphtherie, H. influenzae B, Hepatitis B., Keuchhusten, Kinderlähmung, Masern, Meningitis, Mumps, Pneumokokken, Röteln, Tetanus, HPV vor.

Hierzu gilt es, u.a. auf die folgende Bibliographie zu verweisen :

Hernan M, Jick S, et al : *Recombinant hepatitis B vaccine and the risk of multiple sclerosis. A prospective study.* Neurology 2004.

Naismith.R.T, Cross A H : *Does hepatitis B vaccine cause multiple sclerosis ?* Neurology 2004

Aguilar L, Alvarado O, Soley C, Abdelnour A, Dagan R, Arguedas A. *Microbiology of the middle ear fluid in Costa Rican children between 2002 and 2007.* Int J Pediatr Otorhinolaryngol 2009

Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. *Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.* Lancet Infect Dis 2014

Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, et al. *Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.* Clin Infect Dis 2014

van den Bergh MR, Spijkerman J, Swinnen KM, Francois NA, Pascal TG, Borys D, et al. *Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial.* Clin Infect Dis 2013

Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. *Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.* Clin Infect Dis 2014

Berglund A, Ekelund M, Fletcher MA, Nyman L. *All-cause pneumonia hospitalizations in children <2 years old in Sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.* PLoS One 2014

Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. *The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.* Vaccine 2011

Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, et al. *Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.* Clin Infect Dis 2013

Deceuninck G, De Wals P. *Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease (IPD) in Quebec, Canada* 2014

De Schutter I, Vergison A, Tuerlinckx D, Raes M, Smet J, Smeesters PR et al. (2014). *Pneumococcal aetiology and serotype distribution in paediatric community-acquired pneumonia.* PLoS One 2014

De Wals P, Lefebvre B, Markowski F, Deceuninck G, Defay F, Douville-Fradet M, et al. *Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada*. Vaccine 2014

Domingues CM, Verani JR, Montenegro Renoier EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, et al. *Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study*. Lancet Respir Med 2014

Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, et al. *Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers*. Clin Vaccine Immunol 2010

Griffin MR, Mitchel E, Moore MR, Whitney CG, Grijalva CG. *Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012*. MMWR Morb Mortal Wkly Rep 2014

Guevara M, Ezpeleta C, Gil-Setas A, Torroba L, Beristain X, Aguinaga A, et al. *Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013*. Vaccine 2014

Hanquet G, Lernout T, Vergison A, Verhaegen J, Kissling E, Tuerlinckx D, et al. *Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges*. Vaccine 2011

Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, et al. *Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality*. Clin Infect Dis 2014

Hau I, Levy C, Caeymaex L, Cohen R. *Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media*. Paediatr Drugs 2014

Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. *Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine*. Pediatr Infect Dis J 2013

Kilpi T, Palmu AA, Puumalainen T, Nieminen H. *Effectiveness of the 10-Valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PhiD-CV10) against hospital-diagnosed pneumonia in infants (FINIP TRIAL)*. Soc. Paediatr. Infect. Dis; 2013.

Knol MJ, Sanders EAM, Vlaminckx B, De Melker HE, Van der Ende E. *Incidence of invasive pneumococcal disease in the Netherlands after introduction of 7-valent and 10-valent pneumococcal conjugate vaccination*. Pneumonia 2014

Lepoutre A, Varon E, Georges S, Dorleans F, Janoir C, Gutmann L, et al. *Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012*. Vaccine 2015

Moore M, Taylor T, Pondo T, Barnes M, Petit S, Holtzman C. *Impact of 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) among children <5 years old in the U.S*. Pneumonia 2014

Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, et al. *Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial*. Lancet 2013

Plosker GL. *13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents*. Paediatr Drugs 2013

Poolman J, Frasci C, Nurkka A, Kayhty H, Biemans R, Schuerman L. *Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines*. Clin Vaccine Immunol 2011

Savulescu C, Hanquet, G. *Effectiveness of higher valency conjugate vaccines on invasive pneumococcal disease in Europe: preliminary results of spidnet multicentre project*. Pneumonia 2014

Silfverdal SA, Hogh B, Bergsaker MR, Skerlikova H, Lommel P, Borys D, et al. *Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine*. Pediatr Infect Dis J 2009

Snape MD, Klinger CL, Daniels ED, John TM, Layton H, Rollinson L, et al. *Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial*. Pediatr Infect Dis J 2010

Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF. *Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway*. Vaccine 2013

Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, et al. *Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial*. PLoS Med 2014

Verhaegen, J. *Surveillance des infections à pneumocoques en Belgique*. 2013. Centre National de Référence - Streptococcus Pneumoniae; 2014.

Revised ACIP recommendations for avoiding pregnancy after receiving a Rubella-containing vaccine. MMWR 2001

Reef SE, Frey TK, Theall K et al : *The changing epidemiology of rubelle in the 1990s : on the verge of elimination and new challenges for control an prevention*. JAMA 2002
Tookey PA, Jones G et al : *Rubella vaccination in pregnancy*. Commun Dis Rep CDR wkly 1991

Group A meningococcal carriage in travelers returning from Saudi Arabia. Jama,1988,
Update : assessment of risk for menogococcal disease associated with the Hajj 2001, MMWR 30 marc 2001

Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000